A3P

Log in

Biotech Biom'Up wishes to raise 33,2 M EUR in exchange

The company specializing in surgical haemostasis, Biom'Up announced on Tuesday want to raise 33,2 million euros on the occasion of its IPO to finance its development strategy.

Read more...

EIB grants 20 M EUR loan to biotech Da Volterra

The European Investment Bank (EIB) has granted 20 million euros to the French biotech Da Volterra to accelerate its clinical development program aimed at antibiotic resistance infections.

Read more...

Novartis: EU green light for a drug against a form of leukemia

The Swiss pharmaceutical giant Novartis has obtained the green light from the European Union (EU) for its new drug Rydapt for a serious form of leukemia and three forms of mastocytosis, a rare disease, he said Wednesday.

Read more...

Creation of a very effective triple-antiviral against the AIDS virus

Researchers from the French pharmaceutical group Sanofi and the US National Institutes of Health (NIH) have developed a triple antiviral drug that is highly promising for the prevention and treatment of the AIDS virus.

Read more...

Severe lack of new antibiotics worldwide (WHO)

Faced with the growing "threat" of treatment-resistant bacteria, there is a "serious lack of new antibiotics under development," according to a World Health Organization (WHO) report released Wednesday.

Read more...

a3p-100pxhaut logo

 fren

Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )


  group    administrators A3P
    
& Project Managers

letter   newsletter A3P